Study of etrasimod for immunotherapy side effects withdrawn before starting
NCT ID NCT06521762
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 34 times
Summary
This study aimed to see if adding etrasimod to standard steroid treatment could reduce the need for steroids in people with moderate to severe diarrhea and colon inflammation caused by immune checkpoint inhibitors (cancer immunotherapies). The trial was planned for adults with advanced cancer who were on certain immunotherapy drugs. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR-RELATED DIARRHEA AND COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.